Hung et al. showed that the small molecule SMO antagonist sonidegib (LDE225), a drug approved by the FDA for recurrent basal cell carcinoma, can downregulate the key Shh signaling molecules Ptch1 and Gli1 contributing to autophagy in GSCs [95]. This evidence concerns the gene SMO and basal cell carcinoma.